Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
136 USD | -0.73% |
|
-0.73% | -.--% |
Jun. 20 | Johnson & Johnson Files Application With US FDA Seeking Approval of Tremfya to Treat Crohn's Disease | MT |
Jun. 20 | J&J: launches open, secure digital ecosystem | CF |
Financials (USD)
Sales 2024 * | 88.79B | Sales 2025 * | 92.1B | Capitalization | 356B |
---|---|---|---|---|---|
Net income 2024 * | - | Net income 2025 * | - | EV / Sales 2024 * | 4.01 x |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 3.86 x |
P/E ratio 2024 * |
-
| P/E ratio 2025 * |
-
| Employees | - |
Yield 2024 * |
3.26% | Yield 2025 * |
3.41% | Free-Float | 77.08% |
Latest transcript on Johnson & Johnson
1 week | -0.73% | ||
3 months | -22.29% |
![Extreme 136](/images/extremecours_fleche.png)
![Extreme 136](/images/extremecours_fleche.png)
![Extreme 122](/images/extremecours_fleche.png)
Managers | Title | Age | Since |
---|---|---|---|
Joaquin Duato
CEO | Chief Executive Officer | 61 | 88-12-31 |
Joseph Wolk
DFI | Director of Finance/CFO | 57 | 97-12-31 |
James Swanson
CTO | Chief Tech/Sci/R&D Officer | 58 | 19-11-04 |
Members of the board | Title | Age | Since |
---|---|---|---|
Marillyn Hewson
BRD | Director/Board Member | 70 | 19-04-24 |
D. Davis
BRD | Director/Board Member | 72 | 14-06-18 |
Anne Mulcahy
BRD | Director/Board Member | 70 | 09-10-21 |
![Consensus](/images/consensus_flch.gif)
1st Jan change | Capi. | |
---|---|---|
+51.99% | 803B | |
+18.94% | 324B | |
+11.07% | 303B | |
+16.96% | 243B | |
+2.25% | 228B | |
+11.15% | 217B | |
+7.59% | 164B | |
-3.65% | 155B | |
-1.84% | 117B |
- Stock Market
- Equities
- JNJ Stock
- JNJ Stock